Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02031237 · ClinicalTrials.gov registry record
MRI Study of Changes in Blood-Brain/Tumor-Barrier Permeability in Patients With Brain Metastases During and After Radiotherapy
A clinical trial of Brain Metastases, sponsored by University of Michigan Rogel Cancer Center.
- Completed
- Registry status
- 52
- Enrollment target
- 1
- Study location
NCT02031237 is a study of Brain Metastases that has completed, run by University of Michigan Rogel Cancer Center. The registered enrollment target is 52 participants, below the 212-participant average among 67 other Brain Metastases trials with a reported enrollment target (75% lower). The trial reports 1 study location across 1 state.
The verdict
NCT02031237, a study of Brain Metastases, has completed, sponsored by University of Michigan Rogel Cancer Center.
- COMPLETED
- Registry status
- 52 participants
- Enrollment target
- 1
- Study location
Study Summary
This study aims to assess changes in vascular permeability in the brain tumor, and in the surrounding brain, due to radiation therapy, using Magnetic Resonance Imaging (MRI).
Conditions Studied
Interventions
- RADIATION Fractionated Stereotactic Radiation Therapy (FSRT)
- RADIATION Single Fraction Stereotactic Radiosurgery (SRS)
- RADIATION Fractionated Whole Brain Radiation Therapy (WBRT)
- DEVICE Magnetic Resonance Imaging (MRI) Assessments
Study Locations (1)
Michigan
- University of Michigan Hospital - Ann Arbor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 52 participants |
| Start Date | 2005-04 |
| Est. Completion | 2014-12 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02031237
The ClinicalTrials.gov registry entry for NCT02031237 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 52 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 212-participant average among 67 other Brain Metastases trials with a reported enrollment target (75% lower). The listed sponsor is University of Michigan Rogel Cancer Center, which has 292 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Brain Metastases appearing as the primary indexed condition, and to 4 interventions - of which Fractionated Stereotactic Radiation Therapy (FSRT) is the first listed.
NCT02031237 reports 1 study location spanning 1 distinct geographic area - top geographies include Michigan.
Frequently Asked Questions
What is clinical trial NCT02031237 about?
NCT02031237 is a clinical study titled "MRI Study of Changes in Blood-Brain/Tumor-Barrier Permeability in Patients With Brain Metastases During and After Radiotherapy". This study aims to assess changes in vascular permeability in the brain tumor, and in the surrounding brain, due to radiation therapy, using Magnetic Resonance Imaging (MRI).
What is the current status of trial NCT02031237?
This trial is currently completed. The enrollment target is 52 participants. The study started on 2005-04. Estimated completion is 2014-12.
What conditions does trial NCT02031237 study?
This clinical trial studies the following conditions: Brain Metastases.
What interventions are being tested in trial NCT02031237?
The interventions under investigation include: Fractionated Stereotactic Radiation Therapy (FSRT) (RADIATION), Single Fraction Stereotactic Radiosurgery (SRS) (RADIATION), Fractionated Whole Brain Radiation Therapy (WBRT) (RADIATION), Magnetic Resonance Imaging (MRI) Assessments (DEVICE).
Who is sponsoring clinical trial NCT02031237?
This trial is sponsored by University of Michigan Rogel Cancer Center, which has 292 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02031237 being conducted?
This trial has 1 study location across Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Brain Metastases
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
18F-Fluciclovine PET Amino Acid Evaluation of Brain Metastasis Treated With Stereotactic Radiosurgery
RECRUITING · Phase 1
-
Assess Use of 18F-Fluciclovine for Patients With Large Brain Metastases Treated With Staged Stereotactic Radiosurgery
RECRUITING · Phase 1
-
Stereotactic Radiation & Abemaciclib in the Management of HR+/HER2- Breast Cancer Brain Metastases
RECRUITING · Phase 1
-
Trial of Differential Margins in Single Isocenter Radiosurgery of Brain Metastases
RECRUITING · NA
-
Brain [18F]-FES PET/CT in Patients With Estrogen-Receptor Positive Breast Cancer
RECRUITING · Phase 4
-
7T Brain MRI Scan for Micro-brain Metastasis (microBM) Detection for Patients With Small-cell Lung Cancer (SCLC), Who Decline Prophylactic Cranial Irradiation (PCI)
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.